EP 1294387 A2 20030326 - USE OF PHYLLANTHUS CONSTITUENTS FOR TREATING OR PREVENTING INFECTIONS CAUSED BY FLAVIVIRIDAE
Title (en)
USE OF PHYLLANTHUS CONSTITUENTS FOR TREATING OR PREVENTING INFECTIONS CAUSED BY FLAVIVIRIDAE
Title (de)
VERWENDUNG VON PHYLLANTHUSBESTANDTEILEN ZUR BEHANDLUNG ODER PROPHYLAXE VON INFEKTEN DURCH FLAVIVIRIDAE
Title (fr)
UTILISATION DE CONSTITUANTS DE PHYLLANTHUS POUR TRAITER OU ASSURER LA PROPHYLAXIE D'INFECTIONS PAR FLAVIVIRIDAE
Publication
Application
Priority
- DE 10030139 A 20000620
- EP 0106981 W 20010620
Abstract (en)
[origin: WO0197824A2] The invention relates to the use of one or more phyllanthus constituent(s) or substances or substance mixtures obtained therefrom for preventing or treating infection diseases, which are caused by viruses of the family of Flaviviridae or which are involved in the development or progression of viruses of the family of Flaviviridae. The invention also relates to the use of one or more phyllanthus constituent(s) or substances or substance mixtures obtained therefrom for producing a medicament used in the prevention or treatment of infectious diseases, which are caused by viruses of the family of Flaviviridae or which are involved in the development or progression of viruses of the family of Flaviviridae. The invention additionally relates to the use of one or more phyllanthus constituent(s) or substances or substance mixtures obtained therefrom for inhibiting the multiplication of viruses of the family of Flaviviridae. A method is also disclosed for preventing or treating infectious diseases in a mammal, which are caused by viruses of the family of Flaviviridae or which are involved in the development or progression of viruses of the family of Flaviviridae, whereby one or more phyllanthus constituent(s) or substances or substance mixtures obtained therefrom is/are administered to the mammal. Additionally disclosed is a method for inhibiting the multiplication of viruses of the family of Flaviviridae, whereby one or more phyllanthus constituent(s) or substances or substance mixtures obtained therefrom is/are brought into contact with the viruses. A preferred virus is the hepatitis C virus.
IPC 1-7
IPC 8 full level
A01N 25/00 (2006.01); A61K 36/00 (2006.01); A61K 36/47 (2006.01); A61P 31/12 (2006.01); A61P 31/14 (2006.01)
CPC (source: EP US)
A61K 36/47 (2013.01 - EP US); A61P 31/12 (2017.12 - EP); A61P 31/14 (2017.12 - EP)
Citation (search report)
See references of WO 0197824A2
Citation (examination)
- BAO-EN WANG: "Treatment of chronic liver diseases with traditional Chinese medicine", JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, vol. 15, no. Supl, May 2000 (2000-05-01), pages E67 - E70
- TERRAULT N A: "Treatment of chronic hepatitis B and chronic hepatitis C, XP 008001479", REVIEWS IN MEDICAL VIROLOGY, vol. 6, 1996, pages 215 - 228
- BAO-EN WANG: "Treatment of chronic liver diseases with traditional Chinese medicine", JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, vol. 15, May 2000 (2000-05-01), pages E67 - E70
Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR
DOCDB simple family (publication)
WO 0197824 A2 20011227; WO 0197824 A3 20020510; AU 6908201 A 20020102; CA 2413331 A1 20011227; DE 10030139 A1 20020110; EP 1294387 A2 20030326; US 2002054921 A1 20020509; US 2004028754 A1 20040212
DOCDB simple family (application)
EP 0106981 W 20010620; AU 6908201 A 20010620; CA 2413331 A 20010620; DE 10030139 A 20000620; EP 01947381 A 20010620; US 31196103 A 20030725; US 88446101 A 20010620